Plasmapheresis for neurological disorders

References

• Yeh JH, Cheng CK, Chiu HC. A case report of double-filtration plasmapheresis for the treatment of age-related macular degeneration. Ther. Apher. Dial.12(6), 500–504 (2008).
   PubMedGoogle Scholar
• Couriel D, Weinstein R. Complications of therapeutic plasma exchange: a recent assessment. J. Clin. Apher.9(1), 1–5 (1994).
   PubMedGoogle Scholar
• Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications and management. Am. J. Kidney Dis.23(6), 817–827 (1994).
   PubMed Web of Science ®Google Scholar
• Arbiser JL, Dzieczkowski JS, Harmon JV et al. Leukocytoclastic vasculitis following staphylococcal protein A column immunoadsorption therapy: two cases and a review of the literature. Arch. Dermatol.131(6), 707–709 (1995).
   PubMedGoogle Scholar
• Braun N, Risler T. Immunoadsorption as a tool for the immunomodulation of the humoral and cellular immune system in autoimmune disease. Ther. Apher.3(3), 240–245 (1999).
   PubMedGoogle Scholar
• Hehmke B, Salzsieder E, Matic GB et al. Immunoadsorption of immunoglobulins alters intracytoplasmic type 1 and type 2 T cell cytokine production in patients with refractory autoimmune diseases. Ther. Apher.4(4), 296–302 (2000).
   PubMedGoogle Scholar
• Stegall MD, Gloor J, Winters JL et al. A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am. J. Transplant.6(2), 346–351 (2006).
   PubMed Web of Science ®Google Scholar
• Bengsch S Boos KS, Nagel D. Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock23(6), 494–500 (2005).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Vincent A, Wilson SG et al. Plasmapheresis for myasthenia gravis. N. Engl. J. Med.298(8), 456–457 (1978).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Kurtzke JF. Plasmapheresis in Guillain–Barré syndrome. Neurology35(8), 1105–1107 (1985).
   PubMedGoogle Scholar
• Hauser SL, Dawson DM, Lehrich JR et al. Immunosuppression and plasmapheresis in chronic progressive multiple sclerosis: design of a clinical trial. Arch. Neurol.40(11), 687–690 (1983).
   PubMedGoogle Scholar
• Ruprecht K, Klinker E, Dintelmann T et al. Plasma exchange for severe optic neuritis: treatment of 10 patients. Neurology63(6), 1081–1083 (2004).
   PubMed Web of Science ®Google Scholar
• Schilling S, Linker RA, Konig FB et al. Plasma exchange therapy for steroid-unresponsive multiple sclerosis relapses: clinical experience with 16 patients. Nervenarzt77(4), 430–438 (2006).
   PubMed Web of Science ®Google Scholar
• Weinshenker BG, O’Brien PC, Petterson TM et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann. Neurol.46(6), 878–886 (1999).
   PubMed Web of Science ®Google Scholar
• Watanabe S, Nakashima I, Misu T et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler.13(1), 128–132 (2007).
   PubMed Web of Science ®Google Scholar
• Hench PS, Kendall EC. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin. Proc.24(8), 181–197 (1949).
   PubMed Web of Science ®Google Scholar
• Schmidt J, Gold R, Schonrock L et al. T-cell apoptosis in situ in experimental autoimmune encephalomyelitis following methylprednisolone pulse therapy. Brain123, 1431–1441 (2000).
   PubMed Web of Science ®Google Scholar
• Leussink VI, Jung S, Merschdorf U et al. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch. Neurol.58(1), 91–97 (2001).
   PubMed Web of Science ®Google Scholar
• Dowling PC, Bosch VV, Cook SD. Possible beneficial effect of high-dose intravenous steroid therapy in acute demyelinating disease and transverse myelitis. Neurology30, 33–36 (1980).
   PubMed Web of Science ®Google Scholar
• Bracken MB, Shepard MJ, Collins WF et al. A randomized, controlled trial of methylprednisolone or naloxone in the treatment of acute spinal-cord injury: results of the Second National Acute Spinal Cord Injury study. N. Engl. J. Med.322(20), 1405–1411 (1990).
   PubMed Web of Science ®Google Scholar
• Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. J. Neurol. Neurosurg. Psychiatry50(5), 511–516 (1987).
   PubMed Web of Science ®Google Scholar
• Beck RW, Cleary PA, Anderson MM Jr et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis: the Optic Neuritis study group. N. Engl. J. Med.326(9), 581–588 (1992).
   PubMed Web of Science ®Google Scholar
• Oliveri RL, Valentino P, Russo C et al. Randomized trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology50(6), 1833–1836 (1998).
   PubMed Web of Science ®Google Scholar
• Miller DH, Thompson AJ, Morrissey SP et al. High dose steroids in acute relapses of multiple sclerosis: MRI evidence for a possible mechanism of therapeutic effect. J. Neurol. Neurosurg. Psychiatry55(6), 450–453 (1992).
   PubMed Web of Science ®Google Scholar
• Rieckmann P, Toyka KV, Bassetti C et al. Escalating immunotherapy of multiple sclerosis – new aspects and practical application. J. Neurol.251(11), 1329–1339 (2004).
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bruck W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol. Med.7(3), 115–121 (2001).
   PubMed Web of Science ®Google Scholar
• Lassmann H, Bruck W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol.17(2), 210–218 (2007).
   PubMed Web of Science ®Google Scholar
• Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J. Neuroimmunol.117(1–2), 1–8 (2001).
   PubMed Web of Science ®Google Scholar
• Keegan M, Pineda AA, McClelland RL et al. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology58(1), 143–146 (2002).
   PubMed Web of Science ®Google Scholar
• Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet366(9485), 579–582 (2005).
   PubMed Web of Science ®Google Scholar
• Tselis A, Perumal J, Caon C et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur. J. Neurol.15(11), 1163–1167 (2008).
   PubMed Web of Science ®Google Scholar
• Linker RA, Chan A, Sommer M et al. Plasma exchange therapy for steroid-refractory superimposed relapses in secondary progressive multiple sclerosis. J. Neurol.254(9), 1288–1289 (2007).
   PubMedGoogle Scholar
• Zettl UK, Hartung HP, Pahnke A et al. Lesion pathology predicts response to plasma exchange in secondary progressive MS. Neurology67(8), 1515–1516 (2006).
   PubMedGoogle Scholar
• Lennon VA, Wingerchuk DM, Kryzer TJ et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet364(9451), 2106–2112 (2004).
   PubMed Web of Science ®Google Scholar
• Lennon VA, Kryzer TJ, Pittock SJ et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med.202(4), 473–477 (2005).
   PubMed Web of Science ®Google Scholar
• Moldenhauer A, Haas J, Wascher C et al. Immunoadsorption patients with multiple sclerosis: an open-label pilot study. Eur. J. Clin. Invest.35(8), 523–530 (2005).
   PubMed Web of Science ®Google Scholar
• Palm M, Behm E, Schmitt E et al. Immunoadsorption and plasma exchange in multiple sclerosis: complement and plasma protein behaviour. Biomater. Artif. Cells Immobilization Biotechnol.19(1), 283–296 (1991).
   PubMed Web of Science ®Google Scholar
• Schröder A, Fischer M, Meyer C et al. Plasmapherese in der Eskalationstherapie der Multiplen Sklerose: Verlaufsbeobachtung an 35 Patienten. Akt. Neurol.36, 105–100 (2009).
   Google Scholar
• Odaka M, Yuki N, Yamada M et al. Bickerstaff’s brainstem encephalitis: clinical features of 62 cases and a subgroup associated with Guillain–Barré syndrome. Brain126, 2279–2290 (2003).
   PubMed Web of Science ®Google Scholar
• Fujisato H, Amemiya M, Hayashi Y et al. Treatment with steroids and double filtration plasmapheresis for a case of anti-GQ1b antibody-positive Bickerstaff’s encephalitis. Ther. Apher.3(1), 72–74 (1999).
   PubMedGoogle Scholar
• Markus R, Brew BJ, Turner J et al. Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J. Neurol. Neurosurg. Psychiatry63(4), 551 (1997).
   PubMedGoogle Scholar
• Seales D, Greer M. Acute hemorrhagic leukoencephalitis: a successful recovery. Arch. Neurol.48(10), 1086–1088 (1991).
   PubMedGoogle Scholar
• Murai H, Arahata H, Osoegawa M et al. Effect of immunotherapy in myelitis with atopic diathesis. J. Neurol. Sci.227(1), 39–47 (2004).
   PubMedGoogle Scholar
• Mori M, Kuwabara S, Yoshiyama M et al. Successful immune treatment for non-paraneoplastic limbic encephalitis. J. Neurol. Sci.201(1–2), 85–88 (2002).
   PubMedGoogle Scholar
• Miyamoto K, Kato T, Watanabe H et al. A case of paraneoplastic syndrome accompanied by two types of cancer. J. Neurol. Neurosurg. Psychiatry72(3), 408–409 (2002).
   PubMedGoogle Scholar
• Sommer C, Weishaupt A, Brinkhoff J et al. Paraneoplastic stiff-person syndrome: passive transfer to rats by means of IgG antibodies to amphiphysin. Lancet365(9468), 1406–1411 (2005).
   PubMed Web of Science ®Google Scholar
• Shariatmadar S, Noto TA. Plasma exchange in stiff-man syndrome. Ther. Apher.5(1), 64–67 (2001).
   PubMedGoogle Scholar
• Buckley C, Oger J, Clover L et al. Potassium channel antibodies in two patients with reversible limbic encephalitis. Ann. Neurol.50(1), 73–78 (2001).
   PubMed Web of Science ®Google Scholar
• Vincent A, Buckley C, Schott JM et al. Potassium channel antibody-associated encephalopathy: a potentially immunotherapy-responsive form of limbic encephalitis. Brain127, 701–712 (2004).
   PubMed Web of Science ®Google Scholar
• Seki M, Suzuki S, Iizuka T et al. Neurological response to early removal of ovarian teratoma in anti-NMDAR encephalitis. J. Neurol. Neurosurg. Psychiatry79(3), 324–326 (2008).
   PubMed Web of Science ®Google Scholar
• Mata S, Muscas GC, Naldi I et al. Non-paraneoplastic limbic encephalitis associated with anti-glutamic acid decarboxylase antibodies. J. Neuroimmunol.199(1–2), 155–159 (2008).
   PubMedGoogle Scholar
• Rogers SW, Andrews PI, Gahring LC et al. Autoantibodies to glutamate receptor GluR3 in Rasmussen’s encephalitis. Science265(5172), 648–651 (1994).
   PubMed Web of Science ®Google Scholar
• Basic-Jukic N, Kes P, Bubic-Filipi L et al. Treatment of thrombotic microangiopathies with plasma exchange. Hematology12(1), 63–67 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson CE, Damon LE, Ries CA et al. Thrombotic microangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency virus epidemic. Blood80(8), 1890–1895 (1992).
   PubMed Web of Science ®Google Scholar
• Kato T, Shiratori K, Kobashigawa T et al. Systemic lupus erythematosus with organic brain syndrome: serial electroencephalograms accurately evaluate therapeutic efficacy. Intern. Med.45(2), 95–99 (2006).
   PubMedGoogle Scholar
• Bril V, Ilse WK, Pearce R et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barré syndrome. Neurology46(1), 100–103 (1996).
   PubMed Web of Science ®Google Scholar
• van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barré syndrome: Dutch Guillain–Barré study group. N. Engl. J. Med.326(17), 1123–1129 (1992).
   PubMed Web of Science ®Google Scholar
• Anonymous. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barré syndrome: Plasma Exchange/Sandoglobulin Guillain–Barré Syndrome trial group. Lancet349(9047), 225–230 (1997).
   PubMed Web of Science ®Google Scholar
• Korinthenberg R, Schessl J, Kirschner J et al. Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barré syndrome: a randomized trial. Pediatrics116(1), 8–14 (2005).
   PubMed Web of Science ®Google Scholar
• Arakawa H, Yuhara Y, Todokoro M et al. Immunoadsorption therapy for a child with Guillian–Barre syndrome subsequent to Mycoplasma infection: a case study. Brain Dev.27(6), 431–433 (2005).
   PubMedGoogle Scholar
• Mori M, Kuwabara S, Fukutake T et al. Intravenous immunoglobulin therapy for Miller Fisher syndrome. Neurology68(14), 1144–1146 (2007).
   PubMed Web of Science ®Google Scholar
• Dyck PJ, Daube J, O’Brien P et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N. Engl. J. Med.314(8), 461–465 (1986).
   PubMed Web of Science ®Google Scholar
• Hahn AF, Bolton CF, Pillay N et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain119, 1055–1066 (1996).
   PubMed Web of Science ®Google Scholar
• Mehndiratta MM, Hughes RA, Agarwal P. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst. Rev. (3), CD003906 (2004).
   Google Scholar
• Haas DC, Tatum AH. Plasmapheresis alleviates neuropathy accompanying IgM anti-myelin-associated glycoprotein paraproteinemia. Ann. Neurol.23(4), 394–396 (1988).
   PubMedGoogle Scholar
• Azulay JP, Blin O, Pouget J et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology44(3 Pt 1), 429–432 (1994).
   PubMed Web of Science ®Google Scholar
• Federico P, Zochodne DW, Hahn AF et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology55(9), 1256–1262 (2000).
   PubMed Web of Science ®Google Scholar
• Leger JM, Chassande B, Musset L et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain124, 145–153 (2001).
   PubMed Web of Science ®Google Scholar
• van den Berg LH, Kerkhoff H, Oey PL et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J. Neurol. Neurosurg. Psychiatry59(3), 248–252 (1995).
   PubMed Web of Science ®Google Scholar
• Gorson KC Natarajan N, Ropper AH et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve35(1), 66–69 (2007).
   PubMed Web of Science ®Google Scholar
• Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst. Rev. (4), CD002275 (2002).
   Google Scholar
• Gajdos P, Chevret S, Clair B et al. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis: Myasthenia Gravis Clinical study group. Ann. Neurol.41(6), 789–796 (1997).
   PubMed Web of Science ®Google Scholar
• Qureshi AI, Choudhry MA, Akbar MS et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology52(3), 629–632 (1999).
   PubMed Web of Science ®Google Scholar
• Gold R, Schneider-Gold C. Current and future standards in treatment of myasthenia gravis. Neurotherapeutics5(4), 535–541 (2008).
   PubMed Web of Science ®Google Scholar
• Newsom-Davis J, Murray NM. Plasma exchange and immunosuppressive drug treatment in the Lambert–Eaton myasthenic syndrome. Neurology34(4), 480–485 (1984).
   PubMed Web of Science ®Google Scholar
• Alessi G, De RJ, De BJ et al. Successful immunoglobulin treatment in a patient with neuromyotonia. Clin. Neurol. Neurosurg.102(3), 173–175 (2000).
   PubMedGoogle Scholar
• van den Berg JS, van Engelen BG, Boerman RH et al. Acquired neuromyotonia: superiority of plasma exchange over high-dose intravenous human immunoglobulin. J. Neurol.246(7), 623–625 (1999).
   PubMed Web of Science ®Google Scholar
• Herson S, Lok C, Roujeau JC et al. Plasma exchange in dermatomyositis and polymyositis: retrospective study of 38 cases of plasma exchange. Ann. Med. Interne (Paris)140(6), 453–455 (1989).
   PubMedGoogle Scholar
• Chan A, Weilbach FX, Toyka KV et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin. Exp. Immunol.139(1), 152–158 (2005).
   PubMed Web of Science ®Google Scholar
• Bar-Or A, Calabresi PA, Arnold D et al. Rituximab in relapsing–remitting multiple sclerosis: a 72-week, open-label, Phase I trial. Ann. Neurol.63(3), 395–400 (2008).
   PubMed Web of Science ®Google Scholar
• Hauser SL, Waubant E, Arnold DL et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med.358(7), 676–688 (2008).
   PubMed Web of Science ®Google Scholar
• Linker RA, Lee DH, Stangel M, Gold R. Fumarates for the treatment of multiple sclerosis: potential mechanisms of action and clinical studies. Expert Rev Neurother.8(11), 1683–1690 (2008).
   PubMedGoogle Scholar